Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beyond PD-1: Roche Maps Further Checkpoints On Cancer Immune Cycle

Executive Summary

Roche gave updates on its immunotherapy research at ASCO, setting the stage for an ambitious slate of combination trials with the company's PD-L1 inhibitor atezolizumab.

You may also be interested in...



Lessons Learned In Immuno-Oncology From Former Roche Exec Dan Chen

In an audio interview from the recent ASCO-SITC meeting, Chen weighs in on comparisons of PD-1 and PD-L1 inhibitors, the IDO failures, biomarkers and his new work at the private biotech IGM Biosciences.

Roche Pushes The Boundaries Of Cancer Immunotherapy

Roche is betting that its tumor immunophenotype research can guide combination therapy that will alter the tumor microenvironment, making tumor types than have been resistant to PD-1/L1 inhibitors sensitive to immunotherapy.

Roche’s Immuno-Oncology Arsenal: PD-L1 And Beyond

Roche may be playing catch-up to Bristol-Myers Squibb and Merck & Co in the PD-1/PD-L1 checkpoint development space, but it believes its unique in-house strengths in diagnostics and molecular biology, coupled with partnering, will enable it to play a major role in immuno-oncology.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS056927

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel